Harvard Apparatus Regenerative Technology Schedules Release of First Quarter 2015 Financial Results and Investor Teleconference for May 7th

Conference Call to Occur at 11:00AM ET That Day

HOLLISTON, Mass.--()--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its first quarter ended March 31, 2015 before market trading hours on Thursday, May 7, 2015. A conference call to discuss the company’s first quarter results is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.

Participating in the call will be Tom McNaughton, Chief Financial Officer and Interim Chief Executive Officer, and Saverio La Francesca, Chief Medical Officer, of HART.

Investors can access the live conference call by dialing the following phone numbers: toll-free 877-407-8293, or international: 201-689-8349, and referencing Harvard Apparatus Regenerative Technology, Inc. An audio webcast will also be available at http://public.viavid.com/index.php?id=114411

If you are unable to listen to the live conference call, a replay will be available within approximately 3 hours from the end of the call through 11:59pm ET on May 14, 2015 and will be accessible by dialing toll-free 877-660-6853, or toll/international 201-612-7415, and referencing conference ID “13608552”. The replay will also be made available at the web link above and on the company’s web site, www.harvardapparatusregen.com.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either physical trauma or trachea cancer. Our HART-Trachea technology has been used in several human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.


Harvard Apparatus Regenerative Technology, Inc.:
Tom McNaughton, 774-233-7321
CFO and Interim CEO
Saverio La Francesca, M.D., 774-233-7344

Release Summary

Hart will announce results of its first quarter before market opens on Thursday, May 7, 2015. A conference call to discuss first quarter results is scheduled for 11:00 am that day

Harvard Apparatus Regenerative Technology